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ABSTRACT
Defining new therapeutic strategies to overcome therapy resistance due to tumor 
heterogeneity in colon cancer is challenging. One option is to explore the molecular 
profile of aggressive disseminating tumor cells. The cytoskeleton-associated Death-
associated protein kinase (DAPK) is involved in the cross talk between tumor and 
immune cells at the invasion front of colorectal cancer. Here dedifferentiated tumor cells 
histologically defined as tumor budding are associated with a high risk of metastasis and 
poor prognosis. Analyzing samples from 144 colorectal cancer patients we investigated 
immunhistochemical DAPK expression in different tumor regions such as center, 
invasion front, and buds. Functional consequences for tumor aggressiveness were 
studied in a panel of colon tumor cell lines using different migration, wound healing, 
and invasion assays. DAPK levels were experimentally modified by siRNA transfection 
and overexpression as well as inhibitor treatments. We found that DAPK expression 
was reduced towards the invasion front and was nearly absent in tumor buds. Applying 
the ECIS system with HCT116 and HCT116 stable lentiviral DAPK knock down cells 
(HCTshDAPK) we identified an important role for DAPK in decreasing the migratory 
capacity whereas proliferation was not affected. Furthermore, the migration pattern 
differed with HCTshDAPK cells showing a cluster-like migration of tumor cell groups. 
DAPK inhibitor treatment revealed that the migration rate was independent of DAPK’s 
catalytic activity. Modulation of DAPK expression level in SW480 and DLD1 colorectal 
cancer cells significantly influenced wound closure rate. DAPK seems to be a major player 
that influences the migratory capability of disseminating tumor cells and possibly affects 
the dynamic interface between pro- and anti-survival factors at the invasion front of 
colorectal cancer. This interesting and new finding requires further evaluation.
INTRODUCTION
Death-associated protein kinase (DAPK) is a 
calmodulin regulated and cytoskeleton associated 
serine/threonine kinase [1]. It is a large 160 kDa protein 
composed of several functional domains, including 
a kinase domain, a CaM regulatory domain, eight 
consecutive ankyrin repeats, two putative nucleotide 
binding domains (P-loops), cytoskeletal/ras of complex 
proteins (ROC) domain and a death domain [2, 3]. Due to 
its multi-domain structure, DAPK’s function is not only 
restricted to its kinase activity. Some studies report the 
importance of the scaffold function of DAPK to trigger 
and stabilise multi-protein complexes [4, 5].
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Besides a major role in cell death mechanisms, 
DAPK also regulates cytoskeleton-associated proteins 
to suppress directed migration via blocking of cell 
polarisation [4, 6]. Kuo et al. [6] reported that DAPK has 
an inhibitory effect on talin-H association with integrins 
leading to an abrogation of their inside-out activation 
[7–9]. The phosphorylation of myosin light chain at Ser19 
by DAPK in vivo correlates also with the weakening of the 
structural integrity of the cortical actin network necessary 
for morphological apoptosis-associated changes such as 
cell rounding, shrinking, and detachment [10–13].
Animal studies in syngenic mice have shown that 
lung carcinoma clones with highly aggressive metastatic 
behaviour do not express DAPK, in contrast to their low 
metastatic counterparts [14]. Moreover, DAPK interferes 
with both, early- and late-stage metastatic processes, 
suggesting that DAPK suppresses metastasis through 
multiple mechanisms [15]. In patients with colon cancer, the 
late DAPK down-regulation is associated with metastasis 
to lymph nodes and distant organs, as well as with a shorter 
metastasis-free period and reduced overall survival [15]. 
In line with the anti-metastatic function of DAPK, clinical 
studies indicate that loss of DAPK expression in several 
cancer types, by hypermethylation of the DAPK promoter, is 
associated with advanced tumor stages and more aggressive 
phenotypes [15, 16]. DAPK overexpressing uterine tumors 
may have a growth advantage compared to their DAPK-
negative counterparts [17]. In contrast, Mittag et al. [18] 
describe DAPK promoter hypermethylation as a very early 
event in colorectal carcinogenesis with a high frequency 
in T1 tumors [18]. In inflammation-associated colorectal 
carcinogenesis, DAPK seems to play an important role in 
tumor transformation [19]. Taken together, all these reports 
support an antagonistic duality for DAPK dependent on the 
cellular context and the different experimental settings [20].
Although DAPK is involved in a variety of cellular 
functions such as cell death, migration, and invasion, so far 
in vivo studies do not identify DAPK expression levels in 
different tumor regions such as the tumor center and the tumor 
invasion front. Nevertheless, both regions differ remarkably 
in regard to the number of tumor infiltrating immune cells 
such as T-lymphocytes, macrophages, or dendritic cells 
[21, 22]. The tumor microenvironment and tumor-host-
interaction at the invasion front has been identified as having 
prognostic value in colorectal cancer [21]. We have shown 
previously that in colorectal cancer there is a cross-talk 
between tumor and immune cells mainly at the invasion 
front [23]. Here tumor-associated macrophages influence 
the tumor border gene expression pattern [24] and DAPK-
mediated pro-apoptotic responses [25]. Moreover, so-called 
tumor buds detach from the tumor as single cells or small cell 
clusters (up to five cells) and are also scattered in the stroma 
at the invasion front. Colorectal cancers with high-grade 
tumor budding very often show an infiltrative diffuse growth 
pattern associated with advanced tumor stage and poor 
clinical outcome. Interestingly, tumor buds display very low 
proliferation rates [26], an increased migratory capacity [27] 
and have been linked to an epithelial-mesenchymal transition 
(EMT) [28]. Disseminating tumor buds are known to down-
regulate pro-apoptotic molecules such as apoptosis activating 
factor 1 (APAF1) [29] and only rarely express Caspase-3 [26] 
to protect themselves from anoikis, a form of cell death by 
cell detachment.
So far, DAPK has never been investigated in these 
aggressive tumor cells. Since high-grade tumor budding 
has been associated with metastasis, we aimed to study 
their DAPK expression and to link it to functional 
properties of tumor aggressiveness in vitro.
RESULTS
DAPK expression was decreased towards 
the invasion front and was nearly absent in 
disseminating tumor buds
DAPK was evaluated in a TMA containing 144 
colorectal cancers and was found in the cytoplasm of the 
tumor cells (Figure 1). In comparison to the tumor center 
(76.4% expression), DAPK expression was reduced towards 
the invasion front (72.1% expression) (p = 0.0352) and was 
nearly lost in tumor buds (38.6% expression) (p < 0.0001, 
Figure 1F, 1H; Table 1). Expression of DAPK in tumor 
center, front and within tumor buds was not correlated with 
clinicopathological features (Table 2). Although DAPK in 
the center did not correlate with any prognostic features, 
mucinous cancers showed less DAPK at the invasion front 
(p = 0.0445). Most importantly, a significant loss of DAPK 
in tumor buds was associated with presence of distant 
metastasis (p = 0.0291, Figure 1A). There was, however, 
no association of DAPK expression with survival time.
DAPK loss elevates tumor cell random migration
Owing to the previous proven in vivo reduction of 
DAPK, we performed several in vitro assays to study the role 
of DAPK in tumor cell aggressiveness in colorectal cancer 
cells to understand how DAPK affects cellular functions 
in disseminating tumor cells. As a first step we determined 
the level of DAPK expression in different colorectal tumor 
cell lines to select the suitable in vitro model. Low DAPK 
protein levels were observed in the HCTshDAPK and SW480 
cells whereas DAPK was expressed moderately in HCT116, 
DLD1, and Caco2 cells (Figure 2A). Next, we utilised the 
ECIS technology to examine the effects of DAPK on random 
cell migration. If cells attach, migrate and spread on the small 
gold film electrode of the ECIS array, cellular membranes 
restrict the electrical current, forcing it to flow beneath and 
between the cells, resulting in a dramatic increase in electrical 
impedance. We discovered an increase in electrical impedance 
for HCTshDAPK cells suggesting that migration was elevated 
when DAPK was lost (Figure 2B). Because proliferation was 
inhibited using mitomycin C (10 ng/ml, Sigma) this seems to 
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indicate a clear migratory effect (Figure 2B). In addition, the 
proliferation rate for both cell lines was independent of the 
DAPK status (Supplementary Figure S2).
DAPK expression decreases the migratory 
capacity in wound healing assay
In the second experiment, wound healing migration 
assay of HCTwtDAPK and HCTshDAPK cells with 
culture inserts was performed and cell migration into the 
wounded area was monitored and measured by live-cell 
imaging microscopy (Figure 2C, 2D). After 24 h and 48 h, 
HCTshDAPK cells showed accelerated cell migration into 
the wounded area, whereas wound closure of HCTwtDAPK 
cells was reduced, showing a larger remaining gap (Figure 
2C, 2D), (Supplementary Movie film S1/S2). An almost 
completed monolayer was formed by HCTshDAPK cells 
within 96 h (Supplementary Figure S3). Treatment with 
Figure 1: Immunohistochemical staining of DAPK protein expression in tumors of colorectal cancer patients. Examples 
of tumor center A, D. and invasion front B, E. in comparison with H&E staining (A, B) and DAPK immunohistochemistry (D, E). Overall 
there is only a faint reduction of staining intensity from tumor center to the invasion front. The detailed analyzes of tumor buds in H&E C., 
a standard pan-cytokeratin staining (AE1-3, routine protocol, G. and DAPK immunohistochemistry F. revealed an almost vanishing DAPK 
expression in these small tumor cell clusters (encircled). A summary of the DAPK gradients across these tumor areas in the same samples 
is plotted in H. Of note, the tumor bud pictures highlight the interaction with dense inflammatory infiltrates (C, F, G). I. Statistical analysis 
of DAPK expression in tumor buds of patients with or without metastasis (p = 0.034).
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DAPK inhibitor did not affect cell migration (Figure 2E). 
Interestingly, there was a DAPK-dependent difference in 
migration pattern. Whilst the HCTwtDAPK cells showed 
mostly single cells migrating into the wound, HCTshDAPK 
cells showed a rather cluster-like pattern of larger cell 
groups migrating (Figure 3A). Immunofluorescence 
staining showed DAPK-dependent differences in 
the F-actin reorganisation at the wound margin. In 
HCTwtDAPK cells F-actin distribution was rather cortical, 
demonstrating less-polarised and less-migrating cells. In 
contrast, HCTshDAPK cells showed polarized lamellipodia 
formation of F-actin, typical for migrating cells with a clear 
orientation of the tumor cell nuclei opposite the wound 
margin (Figure 3B).
Next, we examined the effect of DAPK loss in 
DLD1 cells. DAPK knockdown cells demonstrated 
an increase in cell migration in comparison to DLD1 
control cells (Figure 4A) showing a significantly reduced 
percentage of the remaining gap for DAPK siRNA treated 
cells 12 h and 24 h after the scratch was created. The 
inhibition of DAPK catalytic activity in DLD1 cells did 
not reveal any change in the migration rate (Figure 4A).
In SW480 cells with low endogenous DAPK 
expression we used the contrary strategy and investigated 
the effects of overexpressed DAPK on migration. Indeed, 
DAPK overexpression decreased cell migration 12 h and 
24 h after the scratch was created. DAPK overexpressing 
cells demonstrated a significantly higher percentage of 
remaining gap in comparison to SW480 control cells 
(Figure 4B).
Taken together, these results show that DAPK plays 
an important role in decreasing the migratory capacity and 
substrate phosphorylation by DAPK would not appear to 
be crucial for this effect.
DAPK negative cells have a higher invasive 
potential but do less tolerate anchorage 
independence conditions
To study the effect of endogenous DAPK protein 
level on anchorage independent growth in HCTwtDAPK 
and HCTshDAPK cells we performed the soft agar colony 
formation assay. We observed that the number of colonies 
overall (≥50 μm, ≥100 μm, ≥250 μm) did not differ for the 
two cell lines (Figure 5A, 5B). Whilst HCTshDAPK cells 
showed a higher number of smaller colonies (50–100 μm), 
more than 50% of HCTwtDAPK colonies were larger than 
100 μM in size. Since the proliferation rate for both cell 
lines was independent of the DAPK status (Supplementary 
Figure S2) these data are consistent with the assumption 
that DAPK loss induces cell cycle perturbations. In the 
subsequent experiment, we examined the effect of DAPK 
on cell invasion by using Boyden chambers coated with 
Matrigel. We compared the invasion characteristics of 
different colorectal tumor cell lines using the human 
mammary carcinoma cell line MDA-MB-231 as a 
positive control. The invasion potential of HCTshDAPK 
cells was increased 1.8-fold compared with parental 
HCTwtDAPK cells (Figure 5C, Supplementary Figure S4, 
and Supplementary Figure S5).
DISCUSSION
Recently, DAPK has been shown to exert pro- and 
anti-inflammatory as well as pro- and anti-apoptotic 
functions in a context- and stimulus-dependent manner 
[30]. The invasion front of a colorectal tumor is the region 
of tumor-immune cell interaction where inflammation and 
tumor cell dissemination occurs. There are only a few 
reports about the molecular mechanisms by which factors 
at the tumor invasion front alter the gene expression 
profile of neighbouring epithelial cells. Indeed, there 
seems to be a panel of signalling molecules differently 
expressed in the tumor center and the invasion front [31]. 
Kahlert et al. [32] show an invasion-front specific pattern 
of miRNAs when compared to normal tissue. In contrast, 
using laser capture microdissection another study by 
Staub et al. [33] describes rather similar gene expression 
profiles at the invasion front and the inner tumor mass 
where the normal epithelium differs remarkably from the 
tumor compartments. Despite a similar transcriptome, 
the authors suggest that posttranscriptional mechanisms 
in response to tumor and immune cell interaction such 
as protein stabilisation may be much more affected. 
It is known that extracellular proteins of the tumor 
Table 1: Descriptive statistics for DAPK expression in the tumor center, invasion front and tumor 
buds
DAPK No. cases Mean (%) ± SD Median (%) Min (%) Max (%)
Tumor center 144 76.4 ± 15.5 80 20 90
Invasion front 134 72.1 ± 19.6 80 12.5 90
Tumor buds 91 38.6 ± 21.8 40 0 90
Difference center – invasion front 134 4.39 ± 18.2 0 -30 70
Difference front – tumor buds* 89 33.0 ± 19.4 31.6 -20 90
*significant loss of DAPK expression toward invasion front (p = 0.0352) and from front to tumor buds (p < 0.0001)
Oncotarget36778www.impactjournals.com/oncotarget
Table 2: Association between DAPK expression (percent positivity) in tumor center, front and 
tumor buds with clinicopathological features
Feature Center 
(n = 144)
Front 
(n = 134)
Buds 
(n = 91)
N Mean ± 
SD
P-value N Mean ± 
SD
P-value N Mean ± 
SD
P-value
Gender 
(n = 144) Male 66
72.2 ± 
18.9 0.0334 62
74.1 ± 
18.5 0.2751 42
39.7 ± 
22.1 0.63
Female 78 79.9 ± 10.7 72
70.3 ± 
20.5 49
37.6 ± 
21.7
Patient age 
(n = 144) 
(years)
Corr. coeff 144 -0.073 0.3871 134 -0.14 0.1061 91 -0.035 0.736
Tumor size 
(n = 144) 
(cm)
Corr. coeff 144 -0.036 0.6654 134 -0.077 0.3752 91 -0.007 0.945
Histological 
subtype 
(n = 144)
Other 130 75.7 ± 16.0 0.1649 121
73.0 ± 
19.5 0.0445 81
38.5 ± 
21.4 0.939
Mucinous 14 82.8 ± 7.0 13
62.9 ± 
18.1 10
39.5 ± 
25.9
Tumor grade 
(n = 144) G1–2 97
75.4 ± 
15.8 0.2106 90
74.3 ± 
16.7 0.3123 63
38.9 ± 
19.8 0.8896
G3 47 78.4 ± 14.9 44
67.4 ± 
24.0 28
37.9 ± 
25.9
Tumor 
location (n = 
144)
Left 87 76.8 ± 14.7 0.6438 82
73.9 ± 
18.8 0.3217 52
38.2 ± 
20.1 0.9777
Rectum 18 71.0 ± 21.2 18
68.0 ± 
19.5 13
38.1 ± 
23.8
Right 39 77.9 ± 13.9 34
69.6 ± 
21.4 26
39.6 ± 
24.6
pT 
classification 
(n = 144)
pT1–2 38 77.5 ± 14.8 0.6978 36
71.9 ± 
19.2 0.7806 24
34.8 ± 
18.4 0.3177
pT3–4 106 76.0 ± 15.7 98
72.1 ± 
19.8 67
39.9 ± 
22.8
(Continued )
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Feature Center 
(n = 144)
Front 
(n = 134)
Buds 
(n = 91)
N Mean ± 
SD
P-value N Mean ± 
SD
P-value N Mean ± 
SD
P-value
pN 
classification 
(n = 144)
pN0 78 74.5 ± 17.6 0.495 75
72.4 ± 
18.6 0.7753 50
37.7 ± 
20.7 0.5982
pN1–2 66 78.6 ± 12.3 59
71.6 ± 
20.9 41
39.6 ± 
23.3
pM 
classification 
(n = 144)
pM0 125 76.8 ± 15.5 0.1818 117
72.7 ± 
19.3 0.2707 75
40.8 ± 
21.7 0.0291
pM1 19 73.8 ± 15.4 17
67.4 ± 
21.6 16
28.1 ± 
19.3
Venous 
invasion 
(n = 144)
Present 27 76.2 ± 14.3 0.6017 25
71.1 ± 
21.5 0.8807 18
36.4 ± 
25.0 0.6367
Negative 117 76.4 ± 15.8 109
72.3 ± 
19.2 73
39.1 ± 
21.1
Lymphatic 
invasion 
(n = 144)
Present 57 78.5 ± 12.8 0.4896 51
71.7 ± 
21.3 0.5847 39
39.1 ± 
24.3 0.7802
Negative 87 75.0 ± 17.0 83
72.3 ± 
18.5 52
38.2 ± 
19.9
Post-
operative 
therapy 
(n = 144)
None 57 76.1 ± 15.1 0.8771 55
75.5 ± 
20.1 0.6674 34
34.4 ± 
19.8 0.1828
Treated 87 76.5 ± 15.8 79
71.7 ± 
19.3 57
41.1 ± 
22.7
Tumor 
budding 
(10-in-10) 
(n = 144)
Low-grade 78 75.1 ± 15.5 0.1876 71
75.3 ± 
17.3 0.0894 39
46.3 ± 
17.5 0.0024
High-
grade 66
77.9 ± 
15.4 63
68.5 ± 
21.4 52
32.8 ± 
23.0
Survival 
(n = 144)
HR 
(95%CI) 144
0.998 
(0.983–
1.014)
0.7983 134
0.991 
(0.978–
1.004)
0.1805 91
0.996 
(0.981–
1.011)
0.5771
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microenvironment induce genes at the invasion front 
of colorectal liver metastases that are associated with 
epithelial-mesenchymal transition (EMT), a process that 
is a crucial step for tumor dissemination [32]. Indeed, the 
stability of these EMT-inducing transcription factors is 
remarkably regulated by the proteasome system [34].
Our in vivo results suggested that immunohistochemical 
DAPK protein expression was not associated with clinico-
pathological parameters and patient outcome. Nevertheless, 
there is a close agreement with Chen et al. [15] who reported 
that DAPK down-regulation was associated with metastasis 
to lymph nodes and distant organs, as well as with a shorter 
metastasis-free period. We found that the M1 status was 
significantly correlated with low DAPK level in tumor buds.
Immunohistochemical studies by our group and 
others underline the similarities between tumor buds 
and the epithelial-mesenchymal transition (EMT). In 
particular, tumor buds lose E-cadherin from the tumor cell 
membrane and over-express markers of EMT, anoikis-
resistance, invasion and migration [27]. Despite the 
clear associations between tumor budding and a more 
aggressive phenotype, little is known about the molecular 
profile of these disseminating aggressive cells.
To understand the functional role of DAPK at 
the tumor invasion front or in the tumor buds we used 
in vitro models of established colorectal tumor cell 
lines. Interestingly, colony formation assay showed that 
colorectal tumor cells with or without DAPK form the 
Figure 2: Negative effect of DAPK on random and wound healing migration. A. DAPK expression in colorectal cancer cells 
lines. Cell lysates were subjected to immunoblot analyzes with antibodies as indicated. Anti-DAPK (BD Transduction Laboratories) and 
anti-phospho DAPKSer308 (Sigma), with secondary antibodies (anti-mouse IgG peroxidase conjugated; Pierce). Bound antibodies were 
visualised using West Pico chemiluminescent substrate (Pierce) according to the manufacturer’s instructions. Immunoblotting with anti-
GAPDH was used to control equal loading and protein quality. Images were captured using GeneGnome (Syngene). B. Electrical cell 
impedance sensing (ECIS) traces for HCTshDAPK and HCTwtDAPK cells with or without mitomycin C (10 ng/ml) treatment over time. 
Experiment was repeated three times. Representative graphs are shown. C. Quantification of the results describes the change in percentage 
of the wound size at the indicated times for wound healing migration monitored by live-cell imaging microscopy. D. Bright-field imaging 
in wound healing migration assay for HCTshDAPK and HCTwtDAPK cells. Cell migration into wound monitored by live-cell imaging 
microscopy and bright-field images were captured at the indicated times after wounding. Bar, 500 μm. E. A bar graph showing the number 
of cells that migrated after the treatment with DAPK inhibitor. Data are represented as means ± SD from two independent experiments. 
500 μm wound was set as 100% remaining gap.
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same number of colonies, whereby DAPK expressing cells 
develop a higher number of larger colonies. Since these 
differences cannot be attributed to different proliferation 
rates, the delay in colony formation for DAPK low or non-
expressing cells may reflect the induction of an early cell 
cycle arrest or a disturbance in cell cycle progression. In 
this regard, it has been described that the invasion front 
of colorectal carcinomas are zones of low proliferation 
[35]. Here, it was demonstrated that a cell cycle inhibitor 
such as p16 was upregulated at the invasion front and its 
increased expression at the infiltrative front of invasion 
of human colorectal cancer was a prognostic marker for 
poor survival [35, 36]. Since the invasion front represents 
a cancer site where early steps of tumor cell dissemination 
exist, we wanted to explore the role of DAPK loss in 
migration. During directed migration, DAPK functions 
as a potent inhibitor of cell polarisation, whereas DAPK 
inhibits random migration by suppressing directional 
persistence [6]. The DAPK’s motility-inhibitory function 
is thought to have two significant functions in suppressing 
tumor development and/or progression. Firstly, as cell 
migration is necessary for tumor invasion through the 
basement membrane, DAPK may suppress metastasis 
through its effect on cell migration, thereby acting in 
the late stage of tumor progression [6]. Secondly, the 
motility–inhibitory effect of DAPK would be important to 
suppress tumors that have escaped from DAPK-induced 
apoptosis [6]. Indeed, by using Boyden chamber assay, we 
demonstrated that DAPK knockdown in colorectal cancer 
cells resulted in increased cell invasion.
We can only speculate how DAPK is regulated 
in tumor buds and at the invasion front and for this 
we need to consider the role of chronic inflammation 
in carcinogenesis and the function of immune cells 
expressing inflammatory cytokines [37, 38]. Tumor 
cells are recognised by the immune system. Active 
immune escape mechanisms have therefore been 
considered a novel hallmark of cancer [39]. Thus far 
almost nothing is known about DAPK’s role at the 
invasion front of a colorectal tumor representing a 
Figure 3: Confocal immunofluorescence images in wound healing migration assay for HCTshDAPK and HCTwtDAPK 
cells. A. HCTshDAPK and HCTwtDAPK cells were grown for 24–48 h allowing migration under mitomycin C (10 ng/ml) treatment, fixed 
and stained with the endogenous DAPK(red), F-actin (green) and DAPI (blue). Bar, 500 μm. B. HCTshDAPK and HCTwtDAPK cells were 
cultured for 24 h–48 h allowing migration under mitomycin C (10 ng/ml) treatment. Cells were fixed and stained with phalloidin for F actin 
(green) and DAPI (blue). Confocal immunofluorescence images were taken Bar, 50 μm.
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dynamic interface between pro- and anti-tumor factors. 
The infiltrating tumor border configuration and tumor 
budding promote progression and dissemination of 
tumor cells by penetrating the vascular and lymphatic 
vessels [21]. We showed that in Barrett’s carcinomas 
the tumor-associated macrophages express DAPK 
protein and they are rarely detectable in tumors with 
DAPK hypermethylation, thereby suggesting a possible 
cross-talk between immune and tumor cells [40]. 
In recent study from our group, using a cell culture 
model with conditioned supernatants of differentiated/
activated macrophages (U937) and human HCT116 
colorectal tumor cells, we simulated immune cell 
mediated DAPK-associated tumor cell death, reflecting 
the in vivo tumor setting. Indeed, supernatants of 
freshly isolated human macrophages were able to 
induce DAPK expression [25]. Therefore, DAPK 
expression at the invasion front could be regulated 
by inflammatory pathways or by modulations of the 
tumor microenvironment. In this regard we identified 
a new function of DAPK in suppressing TNF-induced 
activation of the pro-inflammatory transcription factor 
STAT3 [19]. Thus the DAPK loss in tumor buds is well 
fitting with the observation that STAT3 is known to 
be upregulated at the invasion front of squamous cell 
carcinoma [41].
We suggest that DAPK down regulation at the 
invasion front and in tumor buds could represent a novel 
immune escape mechanism that requires further study. 
A better understanding of tumor heterogeneity will help 
to define new therapeutic strategies to overcome therapy 
resistance.
Figure 4: DAPK level is a determining factor in tumor cell migration. A. DAPK siRNA transfection in DLD1 cells; effect 
of scratch wound healing after gene silencing. B. Transfection of SW480 with DAPK vector; effect of scratch wound healing after gene 
overexpression. Quantification of the results describes the change in percentage of the wound size at the indicated times. Data shown 
represent means ± SD (n = 3). 500 μm wound was set as 100% remaining gap. Bar, 200 μm. *p < 0.05 for DAPK expression modulation 
compared with control.
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MATERIALS AND METHODS
Patients
A retrospective cohort of 144 patients with primary 
colorectal cancer treated at the Fourth Department of Surgery, 
University of Athens Medical School in Athens, Greece, 
between 2002 and 2007 participated in this study. For each 
patient, a complete histopathological review was undertaken; 
follow-up, survival time and treatment information were 
available from patient charts. None of the patients received 
neoadjuvant therapy. The following information was 
available: gender, age, tumor size, TNM stage (6th edition), 
tumor grade, presence of venous and lymphatic invasion, and 
tumor location (Table 3). Median survival time for the cohort 
was 60 months. The clinical endpoint of interest was overall 
survival. The use of patient material and data was approved 
by the ethics committee of the University of Athens. In order 
to ensure that the patient cohort was representative, Kaplan-
Meier survival curves were plotted for overall survival, 
Figure 5: Colony formation and invasion assay of HCTshDAPK and HCTwtDAPK cells. A. Colonies were fixed and stained 
with crystal violet (0.5%), photographed and counted visually B. Bar, 200 μm. Values are based on different size of colony diameter from 
four different fields. Data shown represent means ± SD (n = 2). C. Transwell invasion assay was performed using the Corning Costar 
Matrigel Matrix coated migration chamber (8 μm pore size). Cells were seeded in the upper chamber in medium with 5% fetal bovine 
serum, and left for the invasion through the matrigel membrane for 24 h and 48 h into the lower chamber well with 10% fetal bovine 
serum medium. The upper surface of the filter was swabbed with cotton to remove non-invading cells. Invading cells were stained with 
0.5%(w/v) crystal violet, quantified by solubilising bound crystal violet in 1%(w/v) sodium dodecyl sulfate (SDS) for 1 hour at 37°C. 
Absorbance was measured at 595 nm; *p < 0.05 compared with control; data represent mean ± SD from two independent experiments with 
two replicates. The photos of invading cells through the Matrigel membrane stained with crystal violet were taken in separated fields at 
100× total magnification.
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Table 3: Patient characteristics (n = 144)
Feature Freq (%)
Gender (n = 144) Male 66 (45.8)
Female 78 (54.2)
Patient age (n = 144) (years) Mean ± SD 69.4 ± 11.5
Tumor size (n = 144) (cm) Mean ± SD 4.6 ± 2.0
Histological subtype (n = 144) Other 130 (90.3)
Mucinous 14 (9.7)
Tumor grade (n = 144) G1–2 97 (67.4)
G3 47 (32.6)
Tumor location (n = 144) Left 87 (60.4)
Rectum 18 (12.5)
Right 39 (27.1)
pT classification (n = 144) pT1–2 38 (26.4)
pT3–4 106 (73.6)
pN classification (n = 144) pN0 78 (54.2)
pN1–2 66 (45.8)
pM classification (n = 144) pM0 125 (86.8)
pM1 19 (13.2)
Venous invasion (n = 144) Present 27 (18.8)
Negative 117 (81.2)
Lymphatic invasion (n = 144) Present 57 (39.6)
Negative 87 (60.4)
Post-operative therapy (n = 144) None 57 (39.6)
Treated 87 (60.4)
Tumor budding (10-in-10) (n = 144) Low-grade 78 (54.2)
High-grade 66 (45.8)
Survival (n = 144) 5-year survival rate % (95%CI) 42.5 (26–58)
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followed by tumor grade, pT, pN, and pM. All showed the 
expected survival differences (p < 0.001, Supplementary 
Figure S1). Tumor budding was scored as low-grade or high-
grade according to the 10-in-10 method [42]. A considerable 
and negative prognostic effect of high-grade budding on 
survival (p < 0.001) was observed.
Tissue microarray and immunohistochemistry 
(IHC)
A next-generation tissue microarray (ngTMA) 
with 0.6 mm tumor cores was constructed [43] and 
included three spots of tumor center, three of invasion 
front and two spots of the densest tumor budding regions, 
where present. The TMA was then sectioned at 3 μm 
and immunohistochemistry was performed with a Leica 
Bond III system (Leica Biosystems, Buffalo Grove, IL, 
USA) in addition to a manual overnight incubation with 
primary antibody anti-DAPK (1:50) (BD Transduction 
Laboratories, Lexington NY) at 37°C. After washing with 
buffer (Dako), sections were incubated with the secondary 
antibody at RT for 30 min. Secondary antibodies were 
EnVision+System HRP linked (goat-anti-mouse or goat-
anti-rabbit, Dako) and positive immunoreactivity was 
detected using DAB+ (Dako) chromogen substrate. Nuclei 
were counterstained with haematoxylin (Dako). Appropriate 
positive and negative controls were included in each run 
of IHC. The percentage of tumor cells that stained positive 
(immunoreactivity above the background, percentage 
of positive cells 10–90%) was quantified/scored by an 
experienced pathologist (TR). Then the average expression 
across the punches was calculated. A separate score for the 
tumor center, invasion front and tumor buds were given.
Statistics
Using a signed-rank test for matched pairs, differences 
in DAPK expression between tumor regions was carried 
out. A non-parametric test (Wilcoxon’s Rank Sum or 
Kruskal Wallis test) was used to test associations of DAPK 
expression in tumor center, invasion front and tumor 
buds with clinicopathological features, while a Pearson’s 
correlation coefficient was used to describe the strength 
of the linear relationship between age, size and DAPK 
expression. Cox regression analysis with hazard ratio and 
95%CI was used to detect survival time differences with 
DAPK, while the Kaplan-Meier method and log-rank test 
were applied for categorical data. P-values < 0.05 were 
considered statistically significant. Analyzes were performed 
using SAS V9.2 (The SAS Institute, Cary NC, USA).
Cell culture and transfection
Human colorectal HCT116, Caco 2, DLD1 and 
SW480 tumor cells were maintained in RPMI and 
human mammary carcinoma cell line MDA-MB-231 was 
maintained in DMEM supplemented with 10% fetal bovine 
serum, penicillin (100 U/ml), and streptomycin (100 μg/
ml). HCT116 DAPK shRNA stable cell line was generated 
using DAPK shRNA lentiviral particles according to the 
manufacturer’s instructions (Santa Cruz), as previously 
described [44]. All cell lines were maintained at 37°C 
in a humidified atmosphere and 5% CO2. Mycoplasma 
contamination was excluded by using the PCR based 
system. Cell lines were authenticated using Multiplex Cell 
Authentication by Multiplexion (Heidelberg, Germany) 
as described recently [45]. As DAPK1 inhibitor we used 
(4Z)-2-phenyl-4-(pyridin-3-ylmethylidene)-4,5-dihydro-
1,3-oxazol-5-one (MolPort). Cells were pre-treated 
for 60 min with 25 μM DAPK inhibitor as previously 
published [5]. Transient transfection was performed 
using Invitrogen’s lipofectamin 2000 according to the 
manufacturer’s recommendations as previously described 
[4, 19].
Western blotting
Equal protein content (30 μg) of cell lysates were 
separated on denaturing SDS-PAGE and transferred onto 
a nitrocellulose membrane prior to probing with antibodies 
as indicated and described previously [4, 19].
Assessment of cell migration by electric cell 
substrate impedance sensing (ECIS)
The effect of endogenous DAPK protein expression 
on cell migration was analyzed applying the ECIS system. 
The cell lines (HCTwtDAPK and HCTshDAPK) were 
seeded in a density of 7500 cells per well on 8W10E 
ECIS arrays (an 8-well chamber slide device - each 
well consisting of 10 active working planar gold film 
electrodes) and grown to confluence over 2 − 5 days. 
To prevent proliferation, the cells were treated with 
mitomycin C (10 ng/ml, Sigma). The eight-well electrode 
array was placed in a humidified cell culture incubator 
at 37°C with 5% CO2 and connected to the electronic 
devices located outside the incubator. The difference 
in the impedance of the two cell lines with different 
DAPK levels was analyzed by comparing the average 
of normalised impedance. The changes in electrical 
resistance were monitored in real time using an ECIS Z 
(Theta) instrument (Applied Bio-Physics) with 8W10E 
ECIS arrays and results expressed as impedance [46, 47].
Wound healing migration assay
A wound healing migration assay was used to 
measure basic cell migration parameters such as speed, 
persistence, and polarity. 3 × 105 cells were seeded in a 
confluent layer with culture inserts (Ibidi, Martinsried, 
Germany) and incubated in RPMI medium. After 24 h, 
cells were treated with mitomycin C (10 ng/ml, Sigma) 
and inserts were removed with sterile forceps to create a 
wound field of ~500 μm. Additionally, cells were seeded in 
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a 6-well plate at a density of 3 × 105cells/well for DAPK 
siRNA transfection, DAPK overexpression, and DAPK 
inhibitor treatment. After the monolayer confluence was 
reached, a straight wound or scratch was then gently 
created in the cell monolayers with a sterile pipette tip. 
Cells detached during the scratch were washed with 
PBS and cultures were then supplemented with the fresh 
medium containing mitomycin C (10 ng/ml, Sigma). The 
cells were incubated and monitored for an additional 
24 h-72 h at 37°C. Bright field microscopy images were 
taken with an inverted microscope Nikon eclipse Ti-U 
(Tokyo, Japan) using 4×/20× objective lens (Nikon). For 
the live cell imaging microscopy, phase contrast images 
were collected at 10 minutes intervals over 60 hours using 
a Keyence BZ9000 microscope, with a 20× objective.
Fixed cells were incubated with blocking buffer 
1%BSA in PBS and then immunofluorescence staining 
was performed with anti-DAPK (1:250) (BD Transduction 
Laboratories, Lexington NY) and F-actin using Alexa 
Fluor 350-conjugated plalloidin (Invitrogen) at 1:10 
(incubated for 30 min at room temperature). Alexa Fluo 
555-conjugated secondary antibody (Invitrogen) was used 
at a concentration 1:500. Cells were mounted on slides with 
ProLong Gold antifade reagent with DAPI (Invitrogen). 
Immunofluorescence images were acquired with Confocal 
Laser Scanning Microscopy system (LSM T-PMT Observer 
Z1, Carl Zeiss Inc.), using a 63x oil objective.
Soft agar assay for colony formation
Colony formation assay on soft agar [48] was 
performed to determine the effect of DAPK expression 
level on anchorage independent growth in HCTwtDAPK 
and HCTshDAPK cells. To prepare the base layer, 0.6% 
agarose in RPMI media was added to 6-well plates and 
allowed to polymerise. The top layer was prepared by 
producing 0.3% agar in cell culture media, and following 
cooling to approximately 40°C, 2000 cells were mixed in 
2 ml of top layer agar and plated over the base layer. Plates 
were allowed to solidify and then incubated at 37°C. 
After 18 days, when colonies reached a size which were 
microscopically clearly visible, colonies were counted 
and images were taken. The cells were stained and fixed 
with 0.5% crystal violet in 20% methanol solution. The 
experiment was repeated in duplicate.
Invasion assay
For invasion assay, 5 × 104 cells were seeded on 
the top of Transwell membranes (8 μm pore size) coated 
with Matrigel basement membrane matrix (Corning 
Costar) following the manufacturer’s instructions. After 
24 h and 48 h of incubation, filters were fixed with 3% 
paraformaldehyde (15 min) and stained with 0.5%(w/v) 
crystal violet, quantified by solubilising bound crystal 
violet in 1%(w/v) sodium dodecyl sulfate (SDS) for 1 hour 
at 37°C. Absorbance was measured at 595 nm.
Cell proliferation assay
Cell Proliferation Kit II XTT (Roche Biodiagnostics 
GmbH, Penzberg, Germany) and Cell Counting kit −8 
(Dojindo Molecular Technologies, Inc. Rockville, MD 
20850, USA) were used according to the manufacturer’s 
instructions to detect cell proliferation. For the growth 
curve assay cells were counted with trypan blue and 
counted at each time point.
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